At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 67 enrolled
Drug / intervention
Durvalumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
In Brief
A Phase 2 clinical trial evaluating Durvalumab, Laboratory Biomarker Analysis, and 1 other intervention for Recurrent Squamous Cell Lung Carcinoma and Stage IV Squamous Cell Lung Carcinoma AJCC v7. Completed, enrolled 67 participants across 1,021 sites.
Detailed Summary
This phase II trial studies how well durvalumab and tremelimumab works in treating patients with stage IV lung cancer that has come back after previous treatment. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedDec 2017
Primary CompletionMay 2020
Study CompletionMar 2022
TodayJul 2026
First PostedDec 14, 2017
Enrollment StartNov 30, 2017
Primary CompletionMay 18, 2020
Study CompletionMar 29, 2022
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 8.5 years ago
Interventions
Durvalumabbiological
Given IV
Laboratory Biomarker Analysisother
Correlative studies
Tremelimumabbiological
Given IV